Alterity sets CEO David Stamler’s base pay at US$525K
The package sets out salary-based severance and medical coverage terms, plus equity vesting provisions for a change of control.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alterity Therapeutics Limited approved changes to CEO and Managing Director Dr David Stamler’s remuneration package, effective October 15, 2026. The package lists a US$525,000 annual base salary, a short-term incentive of up to 100% of annualized base salary based on agreed goals and milestones, and six months’ notice or payment in lieu.
The company intends to seek shareholder approval at its upcoming annual general meeting for termination benefits. Subject to applicable limits, termination without cause provides for a lump sum equal to 100% of then-current annual base salary, plus medical coverage premiums for 12 months or until comparable coverage through a subsequent employer, whichever is earlier, subject to a full release. The terms also provide for equity vesting and other benefits in specified change-of-control circumstances.
Key Figures
Key Terms
Short Term Incentive (STI) financial
Change of Control financial
payment in lieu financial
gross up financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is ATHE CEO David Stamler’s base salary and short-term incentive?
What happens to David Stamler’s equity awards in a change of control?
What severance applies if David Stamler resigns after certain workplace changes?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Changes to Managing Director Terms of Employment |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: October 21, 2026
Exhibit 99.1
Changes to Managing Director Remuneration and Terms of Employment
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 October 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that it has recently undertaken a review of the remuneration package for Dr David Stamler, the Company’s Chief Executive Officer and Managing Director. In completing the review, the directors noted remuneration market comparables, the Company’s increasing level of activities and the progress of results in line with its objectives.
Following this review, the Board confirms that it has approved changes to Dr Stamler's total remuneration package effective from 15 October 2026. In compliance with ASX Listing Rule 3.16.4, the material terms of Dr Stamler's revised remuneration package are summarised in Schedule 1. The Company intends to seek shareholder approval at its upcoming annual general meeting for termination benefits included in Dr Stamler’s revised remuneration package.
This announcement was approved by the Board of Directors of Alterity.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson’s disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company’s lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorization & Additional Information
This announcement was authorized by the Board of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Schedule 1
Material Terms of Revised Remuneration Package
|
Term |
Detail |
||
|
Position |
Chief Executive Officer / Managing Director, effective 21 November 2025 |
||
|
Base Salary |
US$525,000 per annum |
||
|
Short Term Incentive (STI) |
Up to 100% of annualised base salary, based on achievement of agreed goals and milestones |
||
|
Notice Period |
6 months’ notice of termination (or payment in lieu) |
||
|
Severance (Termination without Cause) |
Subject to any applicable limits under the Corporations Act and ASX Listing Rules (in respect of which shareholder approval will be sought), a lump sum payment equal to:
i. 100% of Dr Stamler's then-current annual base salary; and
ii. 100% of the associated premiums to continue group medical coverage for 12 months, or until Dr Stamler becomes eligible for comparable coverage through a subsequent employer, whichever is earlier,
in each case, gross up of any applicable US excise tax, subject to execution of a full release of claims by Dr Stamler. |
||
|
Change of Control |
i. 100% of all unvested equity awards (including stock options, RSUs and all other equity-based compensation) will vest immediately prior to the effective date of a change of control, subject to Dr Stamler executing a full release of claims, continuing to comply with all obligations under his employment agreement, and returning all company property and confidential information.
ii. Any short term incentive (STI) entitlement that has been earned but remains unpaid, or that relates to a current or incomplete STI period, shall accelerate and be payable, calculated in accordance with a formula determined by the Remuneration Committee from time to time.
iii. If Dr Stamler resigns within 90 days of certain events (including a material adverse change in his position, a change of more than 50 miles in his principal work site, or a reduction in his base compensation or other material adverse change in his working conditions, which occur without his consent and are not cured within 30 days),the following severance benefits apply: (a) a lump sum equal to 1x annual base salary; (b) a lump sum equal to his target bonus or any other bonus for the year in which he resigns; and (c) 100% of the associated premiums to continue group medical coverage for 12 months or until he becomes eligible for comparable coverage through a subsequent employer, whichever is earlier. These benefits are in lieu of any other severance entitlements.
In each case, gross up of any applicable US excise tax. |